An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors-Reference-Cited by-同舟云学术

An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors

Published:2017-05-10 Issue:1 Volume:14 Page:
ISSN:1542-6416
Container-title:Clinical Proteomics
language:en
Short-container-title:Clin Proteom

Author:

Li Qing Kay^ORCID,Shah Punit,Tian Yuan,Hu Yingwei,Roden Richard B. S.,Zhang Hui,Chan Daniel W.

Funder

HERA Foundation Ovarian Cancer Outside-the-box

Ovarian Cancer Research Fund Alliance

Drs Li and Ji Family Foundation

NIH/NCI/EDRN

Publisher

Springer Science and Business Media LLC

Subject

Clinical Biochemistry,Molecular Biology,Molecular Medicine,Clinical Biochemistry,Molecular Biology,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12014-017-9152-2.pdf

Reference43 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.

2. Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: IARC Press; 2014.

3. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;389(10022):945–56.

4. Nezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J Obstet Gynecol. 2015;213(3):262–7.

5. Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the european group on tumor markers. Int J Gynecol Cancer. 2016;26:43–51.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Parallel Analyses by Mass Spectrometry (MS) and Reverse Phase Protein Array (RPPA) Reveal Complementary Proteomic Profiles in Triple-Negative Breast Cancer (TNBC) Patient Tissues and Cell Cultures;2024-06-03

2. Aberrant protein glycosylation: Implications on diagnosis and Immunotherapy;Biotechnology Advances;2023-09

3. Mass spectrometry-based proteomics as an emerging tool in clinical laboratories;Clinical Proteomics;2023-08-26

4. Deciphering the Properties and Functions of Glycoproteins Using Quantitative Proteomics;Journal of Proteome Research;2023-04-03

5. Glycoproteomics;Nature Reviews Methods Primers;2022-06-23